Gore tests blood flow reversing embolic protection tech in carotid stent trial:
This article was originally published in Clinica
WL Gore & Associates has begun in the US a study to test the safety and efficacy of its catheter-based system for preventing emboli from escaping to the brain during carotid artery stenting procedures. The Neuro Protection system is unique in that it operates on the principle of reversing the flow of blood at the treatment site, the company said, adding that the technique would provide doctors with the confidence that they have safely directed liberated emboli away from the brain. The study, called EMPiRE has already enrolled its first patients, all of whom have recovered from their procedure without incident, and have been discharged from hospital, said the Flagstaff, Arizona firm.
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.